 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H21F3N2O2 |
| Molar mass | 378.395 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
EPPTB (RO-5212773) is a drug developed by Hoffmann-La Roche which acts as a potent and selective inverse agonistoftrace amine-associated receptor 1 (TAAR1), with no significant activity at other targets. EPPTB is one of the first selective antagonists developed for TAAR1, and has been used to demonstrate an important role for TAAR1 in regulation of dopaminergic signalling in the limbic system.[1] Although EPPTB has high affinity for the mouse TAAR1, it has much lower affinity for rat and human TAAR1, which limits its use in research.[2] While the human and mouse forms of TAAR1 have similar functions and bind similar ligands, the actual binding affinities of individual ligands often vary significantly between the two versions of the receptor.[3]
|
| |||||||
|---|---|---|---|---|---|---|---|
| TAAR1 |
| ||||||
| TAAR2 |
| ||||||
| TAAR5 |
| ||||||
† References for all endogenous human TAAR1 ligands are provided at List of trace amines
‡ References for synthetic TAAR1 agonists can be found at TAAR1 or in the associated compound articles. For TAAR2 and TAAR5 agonists and inverse agonists, see TAAR for references.
| |||||||
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
